Everest Medicines announced that it has submitted a New Drug Application (NDA) to the Department of Health, the Hong Kong Special Administrative Region, China for sacituzumab govitecan (SG) for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) in adult patients who have received two or more prior systemic therapies, at least one of them for metastatic disease. Everest is also closely coordinating with regulatory bodies in mainland China, South Korea and Taiwan to review its applications for SG for adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. In February 2022, Everest announced the approval of Trodelvy® (trade name for SG) in Singapore for second-line mTNBC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.85 HKD | -3.25% | +10.67% | +14.11% |
Apr. 25 | Everest Medicines' Loss Widens in 2023 | MT |
Mar. 28 | Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.11% | 1.01B | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.74% | 15.36B | |
-8.82% | 11.95B | |
-15.66% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- 1952 Stock
- News Everest Medicines Limited
- Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan